Debbane Raymond's Form 4 filing
Crescent Biopharma, Inc.CBIO · filed Jul 30, 2024
- Accession no.
- 0000950170-24-088020
- Filed
- Jul 30, 2024, 5:16 PM ET
- Trade date
- Jul 26-30, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $315.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Debbane RaymondCIK 0001053890 | 10% Owner |
| Invus Public Equities Advisors, LLCCIK 0001340096 | 10% Owner |
| Invus Public Equities, L.P.CIK 0001340097 | 10% Owner |
| Siren, L.L.C.CIK 0002005245 | 10% Owner |
| Invus Global Management, LLCCIK 0002005369 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 26, 2024 | Common Stock | SSaleDisposed | −258,335 | $0.2417F3 | −$62,439.57 | 8,330,729 | Direct | |
| Jul 29, 2024 | Common Stock | SSaleDisposed | −363,949 | $0.2353F4 | −$85,637.2 | 7,966,780 | Direct | |
| Jul 30, 2024 | Common Stock | SSaleDisposed | −756,835 | $0.2209F5 | −$167,184.85 | 7,209,945 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.2451 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.23 to $0.241 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.24 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.